← Leaderboards
Douglas Watson
University Of Maryland Baltimore
$63,554
Attributed
$63,554
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $55.3K · FY2007–09$100K$75K$50K$25K$0
'07
'08
'09
Funding mix
By agency
NIH$63,554 · 4
By mechanism
M01$63,554 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Alonso Heredia$3,865,060
- Satoru Otsuru$3,099,861
- Mark E Shirtliff$2,136,607
- Dudley K. Strickland$27,578,173
- Marcela F Pasetti$26,884,335
Others in their field
Top investigators on “Institution”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,187,810,557
- Leonard Freedman · Leidos Biomedical Research, Inc.$835,530,754
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$566,554,288
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
InstitutionResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthResourcesChildSourceGrantFundingPharmaceutical PreparationsCapsule (Pharmacologic)Powder Dose FormAge-YearsAdolescentRitonavirHiv InfectionsEffectivenessHiv Protease InhibitorsClinical TrialsFormulations, DrugClinical ResearchAtazanavirChildhoodDosage
Grant awards (4)
PEDIATRIC HIV/AIDS COHORT STUDIES: ADOLESCENT MASTER PROTOCOL (AMP)$50,005
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PACTG 1058:INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL D$5,267
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I/II STUDY OF A NOVEL PROTEASE INHIBITOR IN COMBINATION R$4,108
M01 · FY2008 · RR · contact PI
PHASE I/II, OPEN LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASE$4,174
M01 · FY2007 · RR · contact PI